FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2678-2687 June 19, 2008 Number 25 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Cain, M. E. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Dronedarone is a novel antiarrhythmic drug with electrophysiological properties that are similar to those of amiodarone, but it does not contain iodine and thus does not cause iodine-related adverse reactions. Therefore, it may be of value in the treatment of patients with heart failure.

Methods In a multicenter study with a double-blind design, we planned to randomly assign 1000 patients who were hospitalized with symptomatic heart failure and severe left ventricular systolic dysfunction to receive 400 mg of dronedarone twice a day or placebo. The primary end point was the composite of death from any cause or hospitalization for heart failure.

Results After inclusion of 627 patients (310 in the dronedarone group and 317 in the placebo group), the trial was prematurely terminated for safety reasons, at the recommendation of the data and safety monitoring board, in accordance with the board's predefined rules for termination of the study. During a median follow-up of 2 months, 25 patients in the dronedarone group (8.1%) and 12 patients in the placebo group (3.8%) died (hazard ratio in the dronedarone group, 2.13; 95% confidence interval [CI], 1.07 to 4.25; P=0.03). The excess mortality was predominantly related to worsening of heart failure — 10 deaths in the dronedarone group and 2 in the placebo group. The primary end point did not differ significantly between the two groups; there were 53 events in the dronedarone group (17.1%) and 40 events in the placebo group (12.6%) (hazard ratio, 1.38; 95% CI, 0.92 to 2.09; P=0.12). More increases in the creatinine concentration were reported as serious adverse events in the dronedarone group than in the placebo group.

Conclusions In patients with severe heart failure and left ventricular systolic dysfunction, treatment with dronedarone was associated with increased early mortality related to the worsening of heart failure. (ClinicalTrials.gov number, NCT00543699 [ClinicalTrials.gov] .)

Source Information

From the Department of Cardiology, Rigshospitalet, University of Copenhagen (L.K.), and the Department of Cardiology, Gentofte University Hospital (C.T.-P.) — both in Copenhagen; the British Heart Foundation Cardiovascular Research Centre, Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom (J.J.V.M.); Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark (O.G.); the Division of Cardiology, Hôpital Nord, University of Marseille, Marseille, France (S.L.); the Department of Cardiology, University Hospital Maastricht, Maastricht, the Netherlands (H.C.); the Department of Cardiology, Rikshospitalet, Oslo (J.A.); and Cyncron, Copenhagen (J.C.).

Address reprint requests to Dr. Køber at the Department of Cardiology, Rigshospitalet, Blegdamsvej 7, 2100 Copenhagen, Denmark, or at lk{at}heart.dk.

Full Text of this Article

This article has been cited by other articles:

• Falk, R. H., Camm, A. J. (2009). Rethinking the reasons to treat atrial fibrillation? The role of dronedarone in reducing cardiovascular hospitalizations. Eur Heart J 30: 2438-2440 [Full Text]  
• Mason, P. K., DiMarco, J. P. (2009). New Pharmacological Agents for Arrhythmias. Circ Arrhythm Electrophysiol 2: 588-597 [Full Text]  
• Piccini, J. P., Hasselblad, V., Peterson, E. D., Washam, J. B., Califf, R. M., Kong, D. F. (2009). Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.. J Am Coll Cardiol 54: 1089-1095 [Abstract] [Full Text]  
• Chan, P. S., Nallamothu, B. K., Oral, H. (2009). Amiodarone or dronedarone for atrial fibrillation: too early to know the winner?. J Am Coll Cardiol 54: 1096-1098 [Full Text]  
• Marcus, G. M., Keung, E., Scheinman, M. M. (2009). The year in review of clinical cardiac electrophysiology.. J Am Coll Cardiol 54: 777-787 [Full Text]  
• Patel, C., Yan, G.-X., Kowey, P. R. (2009). Dronedarone. Circulation 120: 636-644 [Abstract] [Full Text]  
• Sarwar, R., Cook, S. A. (2009). Genomic Analysis of Left Ventricular Remodeling. Circulation 120: 437-444 [Full Text]  
• Andersen, S. S., Hansen, M. L., Gislason, G. H., Schramm, T. K., Folke, F., Fosbol, E., Abildstrom, S. Z., Madsen, M., Kober, L., Torp-Pedersen, C. (2009). Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. Europace 11: 886-891 [Abstract] [Full Text]  
• Krishnamoorthy, S., Lip, G. Y.H. (2009). How safe is the antiarrhythmic drug therapy in atrial fibrillation?. Europace 11: 837-839 [Full Text]  
• Zimetbaum, P. J. (2009). Dronedarone for Atrial Fibrillation -- An Odyssey. NEJM 360: 1811-1813 [Full Text]  
• The GISSI-AF Investigators, (2009). Valsartan for Prevention of Recurrent Atrial Fibrillation. NEJM 360: 1606-1617 [Abstract] [Full Text]  
• Verma, A. (2009). Alternatives to amiodarone: search for the Holy Grail. Europace 11: 402-404 [Full Text]  
• Doyle, J. F., Ho, K. M. (2009). Benefits and Risks of Long-term Amiodarone Therapy for Persistent Atrial Fibrillation: A Meta-analysis. Mayo Clin Proc. 84: 234-242 [Abstract] [Full Text]  
• Hohnloser, S. H., Crijns, H. J.G.M., van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C., Connolly, S. J., the ATHENA Investigators, (2009). Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. NEJM 360: 668-678 [Abstract] [Full Text]  
• Coletta, A. P., Clark, A. L., Cleland, J. G.F. (2009). Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, {beta}-interferon study, BACH, and ATHENA. Eur J Heart Fail 11: 214-219 [Abstract] [Full Text]  
• McMurray, J., Petrie, M., Swedberg, K., Komajda, M., Anker, S., Gardner, R. (2009). CHAPTER 23 Heart Failure. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Farré, J.#x.;n., Wellens, H. J.J., Rubio, J.#x. M., Benezet, J. (2009). CHAPTER 28 Supraventricular Tachycardias. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Camm, A. J., Kirchhof, P., Lip, G. Y.H., Savelieva, I., Ernst, S. (2009). CHAPTER 29 Atrial Fibrillation. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Coletta, A. P., Cleland, J. G.F., Cullington, D., Clark, A. L. (2008). Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. Eur J Heart Fail 10: 917-920 [Abstract] [Full Text]  
• (2008). All you need to read in the other general journals. BMJ 336: 1462-1463 [Full Text]  
• Cain, M. E., Curtis, A. B. (2008). Rhythm Control in Atrial Fibrillation -- One Setback after Another. NEJM 358: 2725-2727 [Full Text]  
• (2008). Rhythm Control for Atrial Fibrillation Takes Another Hit. Journal Watch Cardiology 2008: 2-2 [Full Text]